

Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

**Safety Direct Solutions - SSTP
Approval**

I, Christopher Paul Burgess, A/Chief Health Officer:

- (a) under section 254(1) of the Act, approve each Scheduled substance treatment protocol specified in Schedule A;
- (b) under section 254(3) of the Act, state that each Schedule substance treatment protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this instrument.

Dated 15/05/2025

Chief Health Officer

Schedule A

Title	Publication Date	Author
Safety Direct Solutions - SSTP	15 May 2025	Medicines and Poisons, Northern Territory Government, NT Health

Safety Direct Solutions - SSTP

Areas Applicable	NT Wide	
Health Professionals authorised by this SSTP	Nurses, and Paramedics employed by or contracted to Safety Direct Solutions Pty Ltd (ABN 19 110 817117)	
Scheduled Substance(s)	Adenosine Adrenaline Amiodarone Atropine Ceftriaxone Dexamethasone Droperidol Enoxaparin Furosemide Glucagon Glyceryl Trinitrate Heparin Hydrocortisone Ipratropium Levetiracetam Lidocaine	Metaraminol Methoxyflurane Metoclopramide Midazolam Naloxone Noradrenaline Ondansetron Rocuronium Salbutamol Tenecteplase Tranexamic Acid Schedule 8 Medicines Fentanyl Morphine Ketamine
Indication, Dose, Route, Frequency	<ul style="list-style-type: none"> Individual substances, or combinations of substances, are to be used according to the indication for which they are being administered as outlined in the Safety Direct Solutions Pty Ltd Clinical Practice Protocols as in force from time to time. Any administration of these substances outside of the approved Guidelines must be under direct instruction of a Medical Practitioner 	
Contraindications and/or Exclusions*	<ul style="list-style-type: none"> Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol Any contraindications or exclusions as outlined in the individual scheduled substance product information Any contraindication or exclusions as outlined in Safety Direct Solutions Pty Ltd Clinical Practice Protocols 	

Health Professional Accreditation Requirements	<p><u>Nurses must:</u></p> <ul style="list-style-type: none"> • Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients • Maintain continuing professional development related to skills and competencies required for delivery of medicines <p><u>Paramedics must:</u></p> <ul style="list-style-type: none"> • Hold registration with the Paramedicine Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients • Maintain continuing professional development related to skills and competencies required for delivery of medicines 		
Chief Health Officer	Signature	Name	Date
	EDOC2025/117176	Christopher Paul Burgess	15/05/2025
Period of effect	This SSTP is in effect until 15/05/2027 unless revoked earlier		
<p>References:</p> <p>* The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration</p>			